Liver cancer remission: is surgery still needed?
NCT ID NCT05349331
First seen Jan 17, 2026 · Last updated Jun 20, 2026 · Updated 21 times
Summary
This study looked at liver cancer patients whose tumors shrank completely after non-surgical treatments like chemoembolization and immunotherapy. Researchers compared those who then had surgery to remove any remaining tissue versus those who simply watched and waited. The goal was to see which approach leads to better survival and fewer recurrences. 74 patients took part in this phase 2 trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-Sen University Cancer Center
Guangzhou, Guangdong, 510000, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Liver resection surgery
What this could lead to
If successful, this could show that some liver cancer patients can safely avoid surgery after a complete response to initial therapy, reducing treatment burden.
What could go wrong
This is a small, phase 2 trial with only 74 participants, so results may not apply broadly. The watch-and-wait approach carries a risk of hidden tumor cells causing recurrence.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.